BioSpace News Archive

INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported its financial results for the year ended December 31, 2021 and provided a business update.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company’s New Drug Application (NDA) to the FDA for Fexapotide Triflutate to seek marketing approval in the U.S. for Fexapotide Triflutate for the treatment of men with benign prostatic hyperplasia (BPH).

Aston Sci. announced the completion of the Series C funding at a scale of USD 22.7 million in December last year.

uLab Systems™, the creator of the uDesign® treatment planning software and uSmile™ clear aligners, has raised $20 million from CareCapital in a convertible note financing.

Cayuga Biotech, an early-stage platform biotechnology company harnessing biomimetic polyphosphate to address severe bleeding and wound healing, announced that Andrea Ashford-Hicks has been named the company’s Chief Executive Officer.

The National Organization for Rare Disorders released a dynamic new resource to educate healthcare nonprofit and advocacy leaders on how a lack of diversity, equity, and inclusion is affecting marginalized groups in the rare disease community.

Eli Lilly and Company will participate in the Barclays Global Healthcare Conference on Tuesday, March 15, 2022.